尿中PAP,γ-SmおよびPAの意義について 第1報:尿中PAP,γ-SmおよびPAの各種前立腺疾患における測定

Abstract

1)前立腺癌18症例(全例既治療)の尿中PAPは有意の低値を示し, この前立腺癌症例中, 治療開始から3年以内に腫瘍の再燃を認めた症例の方が認めなかった症例より有意(危険率P<0.05)に高い値を示した.2)前立腺癌症例の尿中γ-Smは7/15例が測定感度以下であった.3)前立腺癌症例の尿中PAPは測定した8例中6例が測定感度以下であり, 残りの2例も低値を示した

To study the significance of prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostatic specific antigen (PA) in urine, we have determined the urinary levels of these proteins in women and infants, in patients without prostatic disease, in patients with benign prostatic hypertrophy, and in patients with prostatic adenocarcinoma. Women and infants were found to excrete little PAP (27.9 +/- 4.8 ng/mg) and undetectable levels of gamma-Sm except one case, and undetectable levels of PA in the urine. The excretion of PAP in patients with prostatic carcinoma who were either castrated, or treated with endocrine therapy was lower than the levels in women and infants, or the levels in patients without prostatic diseases, or the levels in patients with BPH. Urinary excretion levels of gamma-Sm and PA were undetectable in the patients with well-controlled prostatic carcinoma. The present study suggests that the determination of PAP, gamma-Sm and PA in the urine of patients with prostatic carcinoma may become a useful tool for monitoring of the primary locus of the carcinoma, but additional assays of urinary PAP, gamma-Sm and PA should be measured at regular intervals to be concluded.